[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuromuscular-blockade-reversal-agent\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuromuscular-blockade-reversal-agent":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100590022","sugammadex-induced-clenching-during-neuromuscular-blockade-reversal-100590022",false,"NCT06962007","Sugammadex-Induced Clenching During Neuromuscular Blockade Reversal","A Prospective, Randomized, Double-Blind Study of the Incidence, Severity, and Risk Factors of Clenching Induced by Sugammadex During Neuromuscular Blockade Reversal","Inclusion Criteria:\n\n* Eligible participants are adults aged 19-70 years, American Society of Anesthesiologists (ASA) physical status I-II, undergoing elective surgery under general anesthesia with rocuronium.\n\nExclusion Criteria:\n\n* Exclusion criteria include neuromuscular disorders, renal impairment (creatinine clearance \\\u003C 30 mL\u002Fmin), history of clenching or dental disease, allergy to study drugs, or emergency surgery.",true,"ALL","19 Years","70 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"NA","Study Objective:\n\nThis study aims to evaluate the incidence, severity, and risk factors of sugammadex-induced mouth clenching during neuromuscular blockade (NMB) reversal in adult surgical patients.\n\nStudy Design:\n\nThis prospective, randomized, double-blind, controlled clinical trial enrolls adult patients (ASA physical status I-II, aged 19-70 years) undergoing elective surgery under general anesthesia with rocuronium. Patients will be randomized into four groups to receive either sugammadex at doses of 1 mg\u002Fkg, 2 mg\u002Fkg, or 4 mg\u002Fkg, or a combination of pyridostigmine and glycopyrrolate.\n\nPrimary Outcome:\n\nThe primary outcome is the incidence of clenching within 10 minutes after NMB reversal, assessed by clinical observation, masseter EMG, and airway pressure changes, using a novel five-grade severity scale.\n\nSecondary Outcomes:\n\nSecondary outcomes include the severity of clenching, time to TOF ratio ≥0.9, BIS values at clenching onset, complications, and identification of risk factors such as dose, sex, BIS, age, BMI, and rocuronium dose.\n\nSignificance:\n\nThis study seeks to improve perioperative safety by identifying modifiable risk factors and informing dose adjustments or alternative reversal strategies to prevent sugammadex-induced clenching, particularly in high-risk populations.",[28,29,30,31,32,33],"Neuromuscular Blockade Reversal Agent","Perioperative Complications","Anesthesia, General","Sugammadex","Monitoring, Intraoperative","Masseter Muscle Spasm",[35,36,37],"sugammadex","mouth clenching","neuromuscular blockade reversal","RECRUITING","2026-07-02",{"date":41,"type":42},"2026-07-07","ACTUAL",{"date":44,"type":42},"2025-07-01",{"date":46,"type":22},"2026-10-14",{"name":48,"class":49},"Wonkwang University Hospital","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":50},"100644266","phase-4-the-effect-of-neostigmine-and-sugammadex-on-the-optic-nerve-sheath-diameter-100644266","NCT07666984","The Effect of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter","Comparison of the Effects of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter During the Postoperative Extubation Period","Inclusion Criteria:\n\n* With an ASA physical status of 1-2\n* Patients scheduled for elective surgery\n* Patients willing to participate in the study\n\nExclusion Criteria:\n\n* Patients with heart, liver, kidney, or respiratory failure\n* Brain tumors, hemorrhages, or aneurysms\n* Patients who have undergone eye, cardiovascular, or neurosurgery\n* Eye or neurological diseases or increased intracranial pressure\n* Laparoscopic surgeries\n* Cases not in the supine position\n* Allergy to the medications used\n* Patients who did not provide informed consent to participate in the study.","18 Years","65 Years",{"count":61,"type":22},86,[63],"PHASE4","This study will compare how two drugs, sugammadex and neostigmine-used to reverse muscle relaxation after surgery-affect the size of the optic nerve sheath (the nerve behind the eye) as patients wake up and have their breathing tubes removed. It will also examine the relationship between changes in blood pressure and heart rate during this time and these measurements. This study will be conducted on 86 healthy patients aged 18-65 who will undergo planned surgery at the Çukurova University Faculty of Medicine, Department of Anesthesiology and Reanimation. Patients will be randomly divided into two groups: the sugammadex group and the neostigmine group. All patients will receive standard general anesthesia and rocuronium to relax their muscles. At the end of the surgery, to reverse this effect, patients will be given either sugammadex or a mix of neostigmine and atropine. Group S will receive 2 mg sugammadex per kg, while Group N will receive 0.05 mg neostigmine and 0.02 mg atropine per kg. The width of the optic nerve sheath will be measured by ultrasound 5 minutes after the breathing tube is inserted, 5 minutes before the tube is removed, and 5 minutes after it is removed. Additionally, blood pressure, heart rate, and any complications during the surgery will be tracked and compared between the groups.",[28],[67,68],"Neuromuscular Blockade reversal agent","Optic nerve sheath diameter","2026-06-19",{"date":71,"type":42},"2026-06-24",{"date":73,"type":42},"2026-06-04",{"date":75,"type":22},"2026-07-10",{"name":77,"class":49},"Cukurova University"]